KI failure and cumulative dose of Mutong or Fangji

[Guest guest]

Phil-

 

Do you know I this study was done on guang fangji or han fangji? And

what species of mutong are we talking about? Do we have the same

species here in the US? That is an alarmingly low cumulative dose.

 

-Steve

 

Sent from my iPhone

 

On Apr 9, 2010, at 4:56 AM, " " < wrote:

 

> Hi All,

>

> CUMULATIVE dose of Mutong or Fangji >60g increased the statistical

> risk of KI failure in Taiwan:

>

> Lai MN, Lai JN, Chen PC, Hsieh SC, Hu FC, Wang JD. Risks of kidney

> failure associated with consumption of herbal products containing

> Mutong or Fangchi: a population-based case-control study.

> Am J Kidney Dis. 2010 Mar;55(3):507-18. Epub 2010 Feb 8.

> Institute of Occupational Medicine and Industrial Hygiene, College of

> Public Health, National Taiwan University, Taipei, Taiwan.

> BACKGROUND: Taiwan has a remarkably high incidence of end-stage renal

> disease (ESRD). The objective of this study is to determine the

> association between prescribed herbal products containing

> aristolochic acid and ESRD. STUDY DESIGN: Population-based case-

> control study. SETTING & PARTICIPANTS: All new ESRD cases in Taiwan

> and a simple random sample (200,000 people) drawn from the national

> health insurance reimbursement database in 1997-2002. PREDICTOR: Age;

> sex; hypertension; diabetes; cumulative doses of nonsteroidal anti-

> inflammatory drugs, acetaminophen, and adulterated herbal supplements

> potentially containing aristolochic acid before the development of

> chronic kidney disease; and indications for prescribing such herbs,

> including chronic hepatitis, chronic urinary tract infection, chronic

> neuralgia, or chronic musculoskeletal diseases. OUTCOMES &

> MEASUREMENTS: Occurrence of ESRD through construction of multiple

> logistic regression models. RESULTS: There were 36,620 new ESRD cases

> from 1998 through 2002. After exclusion of cases with chronic kidney

> disease diagnosed before July 1, 1997, there were 25,843 new cases of

> ESRD and 184,851 controls in the final analysis. Women, older age,

> hypertension, and diabetes were significantly associated with

> increased risks of the development of ESRD. After adjustment for

> known risk factors, cumulative doses >60 g of Mutong (OR, 1.47 [95%

> CI, 1.01-2.14] for 61-100 g; OR, 5.82 [95% CI, 3.89-8.71] for >200 g)

> or Fangchi (OR, 1.60 [95% CI, 1.20-2.14] for 61-100 g; OR, 1.94 [95%

> CI, 1.29-2.92] for >200 g) were associated with increased risk of the

> development of ESRD with a dose-response relationship. This

> relationship persisted when analyses were limited to participants who

> consumed <500 pills of nonsteroidal anti-inflammatory drugs and those

> without diabetes. LIMITATIONS: No measurement of renal function, no

> contact with patients, over-the-counter sales were not recorded, and

> potential underestimation of exposure dose for cases and ORs.

> CONCLUSIONS: Consumption of >60 g of Mutong or Fangchi from herbal

> supplements was associated with an increased risk of developing

> kidney failure. Copyright 2010 National Kidney Foundation, Inc.

> Published by Elsevier Inc. All rights reserved. PMID: 20116155

> [PubMed - indexed for MEDLINE]

>

> Best regards,

>

>

>

 

 

 

[Guest guest]

This is interesting Phil, 

Subhuti removed mutong from the formulas at ITM before 2004 because of research

he was receiving about kidney damage. I believe that's reflected in the 2004

edition of " Bag of Pearl " I have an earlier version that still uses mutong.

Patrick

 

--- On Fri, 4/9/10, < wrote:

 

<

KI failure and cumulative dose of Mutong or Fangji

,

Chinese Medicine

Cc: VBMA

Friday, April 9, 2010, 2:56 AM

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Hi All,

 

 

 

CUMULATIVE dose of Mutong or Fangji >60g increased the statistical

 

risk of KI failure in Taiwan:

 

 

 

Lai MN, Lai JN, Chen PC, Hsieh SC, Hu FC, Wang JD. Risks of kidney

 

failure associated with consumption of herbal products containing

 

Mutong or Fangchi: a population-based case-control study.

 

Am J Kidney Dis. 2010 Mar;55(3):507- 18. Epub 2010 Feb 8.

 

Institute of Occupational Medicine and Industrial Hygiene, College of

 

Public Health, National Taiwan University, Taipei, Taiwan.

 

BACKGROUND: Taiwan has a remarkably high incidence of end-stage renal

 

disease (ESRD). The objective of this study is to determine the

 

association between prescribed herbal products containing

 

aristolochic acid and ESRD. STUDY DESIGN: Population-based case-

 

control study. SETTING & PARTICIPANTS: All new ESRD cases in Taiwan

 

and a simple random sample (200,000 people) drawn from the national

 

health insurance reimbursement database in 1997-2002. PREDICTOR: Age;

 

sex; hypertension; diabetes; cumulative doses of nonsteroidal anti-

 

inflammatory drugs, acetaminophen, and adulterated herbal supplements

 

potentially containing aristolochic acid before the development of

 

chronic kidney disease; and indications for prescribing such herbs,

 

including chronic hepatitis, chronic urinary tract infection, chronic

 

neuralgia, or chronic musculoskeletal diseases. OUTCOMES &

 

MEASUREMENTS: Occurrence of ESRD through construction of multiple

 

logistic regression models. RESULTS: There were 36,620 new ESRD cases

 

from 1998 through 2002. After exclusion of cases with chronic kidney

 

disease diagnosed before July 1, 1997, there were 25,843 new cases of

 

ESRD and 184,851 controls in the final analysis. Women, older age,

 

hypertension, and diabetes were significantly associated with

 

increased risks of the development of ESRD. After adjustment for

 

known risk factors, cumulative doses >60 g of Mutong (OR, 1.47 [95%

 

CI, 1.01-2.14] for 61-100 g; OR, 5.82 [95% CI, 3.89-8.71] for >200 g)

 

or Fangchi (OR, 1.60 [95% CI, 1.20-2.14] for 61-100 g; OR, 1.94 [95%

 

CI, 1.29-2.92] for >200 g) were associated with increased risk of the

 

development of ESRD with a dose-response relationship. This

 

relationship persisted when analyses were limited to participants who

 

consumed <500 pills of nonsteroidal anti-inflammatory drugs and those

 

without diabetes. LIMITATIONS: No measurement of renal function, no

 

contact with patients, over-the-counter sales were not recorded, and

 

potential underestimation of exposure dose for cases and ORs.

 

CONCLUSIONS: Consumption of >60 g of Mutong or Fangchi from herbal

 

supplements was associated with an increased risk of developing

 

kidney failure. Copyright 2010 National Kidney Foundation, Inc.

 

Published by Elsevier Inc. All rights reserved. PMID: 20116155

 

[PubMed - indexed for MEDLINE]

 

 

 

Best regards,

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[Guest guest]

Hi All,

 

CUMULATIVE dose of Mutong or Fangji >60g increased the statistical

risk of KI failure in Taiwan:

 

Lai MN, Lai JN, Chen PC, Hsieh SC, Hu FC, Wang JD. Risks of kidney

failure associated with consumption of herbal products containing

Mutong or Fangchi: a population-based case-control study.

Am J Kidney Dis. 2010 Mar;55(3):507-18. Epub 2010 Feb 8.

Institute of Occupational Medicine and Industrial Hygiene, College of

Public Health, National Taiwan University, Taipei, Taiwan.

BACKGROUND: Taiwan has a remarkably high incidence of end-stage renal

disease (ESRD). The objective of this study is to determine the

association between prescribed herbal products containing

aristolochic acid and ESRD. STUDY DESIGN: Population-based case-

control study. SETTING & PARTICIPANTS: All new ESRD cases in Taiwan

and a simple random sample (200,000 people) drawn from the national

health insurance reimbursement database in 1997-2002. PREDICTOR: Age;

sex; hypertension; diabetes; cumulative doses of nonsteroidal anti-

inflammatory drugs, acetaminophen, and adulterated herbal supplements

potentially containing aristolochic acid before the development of

chronic kidney disease; and indications for prescribing such herbs,

including chronic hepatitis, chronic urinary tract infection, chronic

neuralgia, or chronic musculoskeletal diseases. OUTCOMES &

MEASUREMENTS: Occurrence of ESRD through construction of multiple

logistic regression models. RESULTS: There were 36,620 new ESRD cases

from 1998 through 2002. After exclusion of cases with chronic kidney

disease diagnosed before July 1, 1997, there were 25,843 new cases of

ESRD and 184,851 controls in the final analysis. Women, older age,

hypertension, and diabetes were significantly associated with

increased risks of the development of ESRD. After adjustment for

known risk factors, cumulative doses >60 g of Mutong (OR, 1.47 [95%

CI, 1.01-2.14] for 61-100 g; OR, 5.82 [95% CI, 3.89-8.71] for >200 g)

or Fangchi (OR, 1.60 [95% CI, 1.20-2.14] for 61-100 g; OR, 1.94 [95%

CI, 1.29-2.92] for >200 g) were associated with increased risk of the

development of ESRD with a dose-response relationship. This

relationship persisted when analyses were limited to participants who

consumed <500 pills of nonsteroidal anti-inflammatory drugs and those

without diabetes. LIMITATIONS: No measurement of renal function, no

contact with patients, over-the-counter sales were not recorded, and

potential underestimation of exposure dose for cases and ORs.

CONCLUSIONS: Consumption of >60 g of Mutong or Fangchi from herbal

supplements was associated with an increased risk of developing

kidney failure. Copyright 2010 National Kidney Foundation, Inc.

Published by Elsevier Inc. All rights reserved. PMID: 20116155

[PubMed - indexed for MEDLINE]

 

Best regards,